Pharmacological management of behavioural and psychological disturbance in dementia

Human Psychopharmacology - Tập 21 Số 1 - Trang 1-12 - 2006
Mervat N. Kozman1, John Wattis2, Stephen Curran2,3
1Department of Adult Psychiatry, Briary Wing, Harrogate General District Hospital, Lancaster Park Road, Harrogate UK
2Ageing and Mental Health Research Group, School of Human and Health Sciences, University of Huddersfield, UK
3Calder Unit, South West Yorkshire Mental Health NHS Trust, Wakefield, UK

Tóm tắt

Abstract

Behavioural and psychological symptoms in patients with dementia are common, distressing and often difficult to manage. This review evaluates a range of drugs commonly used to manage these symptoms including antipsychotics, anticonvulsants, antidementia drugs and antidepressants.

The risks and benefits of individual treatments are discussed and the relatively poor evidence base and need for further research is highlighted. Copyright © 2006 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1097/00019442-199300140-00012

10.1097/00004714-199902000-00014

10.1185/030079904125004204

Ballard C, 2005, Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: a randomised, double‐blind, placebo‐controlled trial, Br Med J, 330, 874, 10.1136/bmj.38369.459988.8F

Beber CR, 1965, Management of behaviour in the institutionalized aged, Dis Nerv Syst, 26, 591

10.4088/JCP.v64n0205

10.1185/030079904X16777

10.1002/(SICI)1099-1166(199705)12:5<519::AID-GPS534>3.0.CO;2-Q

10.1176/ajp.147.12.1640

10.1093/geronj/48.6.M255

10.1111/j.1532-5415.1986.tb04303.x

10.1300/J089v12n03_03

Cooper J, 2003, Buspirone for anxiety and agitation in dementia, J Psychiatry Neurosci, 28, 496

10.1097/00019442-200303000-00004

10.1212/WNL.44.12.2308

Curran S, 2004, Practical Management of Dementia—A Multi‐Professional Approach

10.1002/gps.1365

10.1212/WNL.53.5.946

10.1212/WNL.57.4.613

10.1016/S0149-2918(04)90172-5

10.1002/gps.998

Food and Drug Administration—US FDA.2005.Off‐label use of atypical antipsychotics linked to increased mortality in the elderly.www.medscape.com

10.1111/j.1532-5415.2004.52406.x

10.1185/030079902125001452

10.1136/bmj.330.7496.857

10.1002/gps.1341

Gill SS, 2005, Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study, Br Med J

10.1176/appi.ajgp.8.3.221

10.1097/00004714-200002000-00015

10.1212/01.WNL.0000129990.32253.7B

10.1097/00019442-199400210-00011

Jewart RD, 2005, Cognitive, behavioural and physiological changes in Alzheimer's disease patients as a function of incontinence medications, Am J Psychiatry, 13, 324

Jost BC, 1996, The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study, Am J Geriatr Psychiatry, 4, 383

Kaufer D, 1998, Assessing the effects of donepezil in Alzheimer's patients and its impact on caregivers, J Am Geriatr Soc, 46, 198

10.1097/00019442-199923740-00011

10.1002/(SICI)1099-1166(200004)15:4<338::AID-GPS119>3.0.CO;2-U

10.1136/bmj.38125.465579.55

Lonergan E, 2002, the Cochrane Library

10.1176/appi.ajp.157.5.708

10.1016/S0140-6736(00)03399-7

10.1016/S0893-133X(01)00365-7

MonschAU Heiter‐ReiffenstuhlI BraendleD.2002.Galantamine reduces behavioural and psychological disturbances and related caregiver burden in Alzheimer's disease patients. Poster at the 6th Congress of the European Federation of Neurological Societies Vienna.

10.1093/ageing/afg061

10.1192/bjp.157.6.894

10.1017/S1041610292001017

Oflasson K, 1992, Fluvoxamine in the treatment of the demented elderly patients: a double‐blind placebo‐controlled study, Acta Psychiatrica Scandinavica, 851, 453

10.1097/00019442-200111000-00008

Overall JE, 1962, The Brief Psychiatric Rating‐Scale, Psychol Rep, 10, 799, 10.2466/pr0.1962.10.3.799

10.1016/S0140-6736(81)91930-9

10.1097/00019442-200102000-00009

10.1002/mds.1204

Reisberg B, 1987, Behavioural symptoms in Alzheimer's disease, phenomenology and treatment, J Clin Psychiatry, 48, 9

10.1185/030079902125000561

10.1592/phco.23.2.217.32084

10.1155/1999/168023

Rosler M, 2002, The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia, Int J Clin Psych, 127, 20

10.1192/bjp.168.2.149

10.1097/00019442-199524310-00004

10.1002/gps.930061003

SchneiderL YeungP SweitzerD et al.1999.Effects of quetiapine reducing hostility and psychosis in patients with Alzheimer's disease/Poster NR657presented at the 152nd American Psychiatric Association (APA) meeting; 1999 May 15–20; Washington DC.

10.1097/00002093-199509040-00010

10.1001/archpsyc.57.10.968

Tariot P, 1994, Handbook of Dementing Illnesses

10.1176/ajp.155.1.54

10.1212/WNL.54.12.2269

10.1111/j.1532-5415.2001.49266.x

Tariot PN, 2002, Quetiapine in nursing home residents with Alzheimer's dementia and psychosis, Am J Geriatr Psychiatry, 10, 93

10.1001/jama.291.3.317

Verny M, 2004, Reduced psychotropic drug use in patients with Alzheimer's disease receiving rivastigmine: results of the EXELAN study, J Drug Ass, 7, 1

10.1177/089198878800100408

10.1159/000074281